Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection

Inclusion Criteria: * o At least 18 years of age * Male or female patient who had DMEK within the past 1 to 7 weeks. * Patient is able and willing to administer eye drops. * Patient is able to comprehend and has signed the Informed Consent form. * Patient is likely to complete the 11-month study duration. Exclusion Criteria: * o A history of a previous rejection episode in the study eye * A patient exhibiting intraocular inflammation. * A patient with a known sensitivity to any of the ingredients in the study medications * A patient who has a condition (i.e., UNCONTROLLED systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study * A patient with abnormal eyelid function. * A patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis. * Presence of any ocular disease that would interfere with the evaluation of the study treatment. However, patients with a history of cystoid macular edema, age-related macular degeneration, controlled glaucoma, corneal neovascularization, and other non-interfering comorbidities may be enrolled. * A patient with a history of non-compliance with using prescribed medication. * Patients who are pregnant or planning to become pregnant within the duration of the study